ArticleJA clinical reports2025
Effect of flumazenil on recovery of memory following recovery of consciousness from general anesthesia with remimazolam: a randomized, open-label, single-center controlled trial.
Article in JA clinical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecovery of consciousness from general anesthesia with remimazolam, an ultrashort-acting benzodiazepine, occurs rapidly. However, patients after recovery of consciousness from general anesthesia with remimazolam often experience periods of amnesia. Remimazolam can be antagonized by flumazenil. Therefore, we investigated the effect of flumazenil on the recovery of memory following the recovery of consciousness from general anesthesia with remimazolam.
methodsThis single-center randomized controlled trial was conducted from November 2023 to July 2024. Forty-four patients undergoing breast surgery were enrolled. The patients received general anesthesia with remimazolam and remifentanil and were randomized to receive flumazenil after recovery of consciousness or not. The recovery of the memory was evaluated by showing an A4-size poster (illustration) to the patients and asking them to remember the poster every 1 h. Furthermore, the effect-site concentration of remimazolam was calculated using the Masui model.
resultsAll 44 patients (22 with and 22 without flumazenil) were assessed. The percentage of patients who remembered the poster 1 h after regaining consciousness was significantly higher in the flumazenil group than in the no flumazenil group (95.5 vs 40.9%; p < 0.001). All patients could recall the poster within 2 h postoperatively. The mean effect-site concentration of remimazolam at the time of consciousness recovery was similar between the two groups (0.31 ± 0.08 µg/mL).
conclusionsFlumazenil significantly accelerated the recovery of memory retention in patients who had recovered consciousness from general anesthesia with remimazolam. However, even without the administration of flumazenil, all patients successfully recovered their memory within 2 h after regaining consciousness.
trial registrationThis clinical trial was registered at the University Hospital Medical Information Network (UMIN) Center on November 01, 2023 (UMIN-CTR: UMIN000052659).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.